Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.

Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine. The lawsuit, filed ...

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced ...